ANDA 213229, held by Hikma. Succinylcholine Chloride.
As of Nov 16, 2026, ANDA 213229 (Succinylcholine Chloride), held by Hikma, was first approved by FDA on Jun 12, 2020, with 4 approved supplements and 0 published complete response letters.
Succinylcholine Chloride Injection is indicated in adults and pediatric patients: as an adjunct to general anesthesia to facilitate tracheal intubation to provide skeletal muscle relaxation during surgery or mechanical ventilation.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 12, 2020 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Succinylcholine Chloride20MG/ML · injectable;injection | Succinylcholine Chloride | Rx |
| Sep 27, 2023 | Supplement 7Labeling · Standard review | Approved | None posted |
| Sep 26, 2022 | Supplement 4Labeling · Standard review | Approved | None posted |
| Apr 20, 2022 | Supplement 3Labeling · Standard review | Approved | None posted |
| Nov 24, 2020 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jun 12, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters